2017
DOI: 10.6002/ect.2016.0346
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Abstract: Preformed donor-specific antibodies against human leukocyte antigen can induce antibody-mediated rejection after organ transplant. Hence, future transplant recipients undergo pretransplant screening for preformed antibodies (ie, virtual crossmatch). Subsequently, prospective (analytic) crossmatching is performed using conventional, complementdependent cytotoxicity assays and/or flow cytometrybased methods. The present article reviews factors that must be considered when unexpected, positive, prospective crossm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 35 publications
0
3
0
1
Order By: Relevance
“…Si bien la FCXM es un método con excelente sensibilidad y especificidad, también comparte varios de los problemas asociados a las pruebas celulares (24,37,38). Entre los problemas más importantes, podemos mencionar la unión inespecífica de las inmunoglobulinas a los FcR, los autoanticuerpos no HLA y el uso de anticuerpos terapéuticos para inducción de la inmunosupresión, como rituximab (anti-CD20), daclizumab (anti-CD25), alemtuzumab (anti-CD52) y globulina antitimocítica, que dan lugar a resultados falsos positivos (39)(40)(41)(42)(43).…”
Section: Prueba Cruzada Por Citometría De Flujounclassified
“…Si bien la FCXM es un método con excelente sensibilidad y especificidad, también comparte varios de los problemas asociados a las pruebas celulares (24,37,38). Entre los problemas más importantes, podemos mencionar la unión inespecífica de las inmunoglobulinas a los FcR, los autoanticuerpos no HLA y el uso de anticuerpos terapéuticos para inducción de la inmunosupresión, como rituximab (anti-CD20), daclizumab (anti-CD25), alemtuzumab (anti-CD52) y globulina antitimocítica, que dan lugar a resultados falsos positivos (39)(40)(41)(42)(43).…”
Section: Prueba Cruzada Por Citometría De Flujounclassified
“…According to this, background FC-XM reactivity is higher in tests with B lymphocytes than in tests with T lymphocytes, partly because of nonspecific immunoglobulin binding by Fc receptors and surface immunoglobulins on the surface of B cells, as well as other Abs reacting with lymphocytes. Other substances present in the recipient's serum can also bind to Fc receptors (eg, auto-Abs) 8,22 or may target lymphocytes (eg, therapeutic Abs) 8,23 ( Figure 2). False-positive XM may therefore be caused by autoimmune disease.…”
Section: Improved Fc-xm By Avoiding False-positive Reactions On B-cmentioning
confidence: 99%
“…7 FC-XM assay is therefore the most sensitive cell-based method for detecting DSAs. However, inconsistencies between virtual-XM (the donor's HLA genotype is compared with the recipient's anti-HLA Ab specificity assessed prior to transplantation in a single-antigen flow bead assay or a phenotype panel bead assay) and FC-XM are not uncommon and the clinical pathologist must understand and explain these discrepancies, 8,9 as the use of FC-XM and single antigen beads assays are still limited by methodological and clinical variations. Especially, DSA strength correlates with CDC-and FC-XM results [10][11][12] or denatured class I HLA antibodies, detected by single antigen beads assays, provide negative XM.…”
mentioning
confidence: 99%
See 1 more Smart Citation